Business
RepliCel Life Sciences Announces Initiation of Clinical Site and Participant Recruitment for European Skin Aging Study
RepliCel Life Sciences Announces Initiation of Clinical Site and Participant Recruitment for European Skin Aging Study.
About this update from Replicel Life Sciences Inc.
[{"type":"text","content":"\n\n\n\nRepliCel Life Sciences Announces Initiation of Clinical Site and Participant Recruitment for European Skin Aging Study\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n\n\n\n\n\n\nRepliCel Life Sciences Announces Initiation of Clinical Site and Participant Recruitment for European Skin Aging Study\nPR Newswire\nVANCOUVER, Sept. 15, 2015\n\n\n\nClinical trial site located at IUF Leibniz-Institut für umweltmedizinische Forschung GmbH in Germany\n\n\n\nVANCOUVER, Sept. 15, 2015 /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V: RP), a clinical stage regenerative medicine company focused on the development of autologous cell therapies, today announced that its European Phase 1 study (NCT02391935) of intradermal injections of RCS-01 to treat aged and sun damaged skin has been initiated at the IUF Leibniz-Institut für umweltmedizinische Forschung GmbH in Germany.  To learn more about the trial, or to determine if you meet eligibility criteria, please visit https://www.clinicaltrials.gov/ or click here.\n\n\"We anticipate fast patient enrollment and 6-month data in autumn 2016. We look forward to analyzing the safety of triple injections of our autologous cellular product, RCS-01, as a potential treatment for intrinsic aging, wrinkling and solar degeneration of the skin,\" stated Dr. Rolf Hoffmann, Chief Medical Officer & Director of RepliCel.  \"We will also be measuring 10 different biomarkers related to skin aging which will give us a good indication of the changes in the skin. The repair of damaged skin at the cellular level, via the natural cell-based production of type 1 collagen and other important matrix molecules, would fundamentally change the aesthetics market currently flooded with dermal products that temporarily reverse the signs of aging using fillers and hyaluronic acids.\"\n\n\"This RCS-01 trial initiation represents the second clinical trial of  RepliCel's non-bulbar dermal sheath fibroblast (NBDS) platform to be initiated this year, the first being RCT-01 in Canada for chronic t...